Kirkland & Ellis LLP represents Abbott (NYSE: ABT) in its definitive agreement with Alere Inc. (NYSE: ALR) announced today in which Abbott will acquire Alere, the Massachusetts-based point of care testing company. Through this transaction Abbott is significantly advancing its global diagnostics presence and leadership. Under the terms of the agreement, Abbott will pay $56 per common share at a total expected equity value of $5.8 billion. More information on the transaction is available here.
The Kirkland team is led by corporate partners Daniel Wolf, David Feirstein, Laura Sullivan and John Kupiec.